2014~2016年我院门诊口服非甾体抗炎药的应用动态分析

2014~2016年我院门诊口服非甾体抗炎药的应用动态分析

李曼,任金妹,谢宁

复旦大学附属中山医院青浦分院,复旦大学附属中山医院青浦分院,复旦大学附属中山医院青浦分院

收稿日期:2018-02-05 修回日期:2018-02-05 出版日期:2018-03-25
基金资助:
上海市青浦区卫计委课题（项目编号：W2015-03；项目名称：注射用吲哚美辛温度敏感即型凝胶的研制）

Dynamic Analysis of Oral Nonsteroid Anti-inflammatory Drugs Used in Outpatients in Our Hospital During the Year of 2014~2016

LI Man,REN Jinmei and Xie Ning

Department of Pharmacy,Qingpu Branch of Zhongshan Hospital,Department of Pharmacy,Qingpu Branch of Zhongshan Hospital,Department of Pharmacy,Qingpu Branch of Zhongshan Hospital

Received:2018-02-05 Revised:2018-02-05 Online:2018-03-25

摘要/Abstract

摘要： 目的：分析我院2014~2016年门诊非甾体抗炎药（NSAIDs）的应用情况，为其临床合理应用与管理提供参考。方法：利用我院门诊药房信息查询系统，对门诊NSAIDs用药量、销售金额、用药频度（DDDs）、日均费用（DDC）和排序比（B/A）等进行统计、分析。结果：2014~2016年我院NSAIDs口服药品品种与结构保持稳定，药品金额呈现逐年上升的趋势，乙酰水杨酸肠溶片（100 mg）连续3年DDDs居于第一位，DDC为洛芬待因缓释片最高。结论：我院门诊口服NSAIDs使用量及金额随着医院的不断发展而增加，各种药品使用基本合理。临床用药向着低毒、缓释的方向发展。NSAIDs的临床使用需要注意不良反应的防治策略。

Abstract: Objective： To analyze the application of nonsteroidal anti-inflammatory drugs (NSAIDs) in outpatients in our hospital from 2014 to 2016， and to provide reference for clinical rational application and management. Methods： Using the information inquiry system of outpatient pharmacy in our hospital， the statistics of NSAIDs sales amount， DDDs， daily average cost (DDC) and sorting ratio (B/A) were analyzed. Results： In the year of 2014~2016， the variety and structure of NSAIDs used in our hospital were stable， and NSAIDs sales amount was increasing. Acetylsalicylic acid enteric-coated tablets(100 mg) was the first in DDDs for 3 consecutive years. Ibuprofen-codeine sustained release tablets was the first in DDC. Conclusion： The sales amount of NSAIDs in the outpatient of our hospital increased with the continuous development of the hospital. The utilization of NSAIDs in our hospital is generally rational， and the clinical medication is developing in the direction of extended release and low toxicity. The clinical use of NSAIDs requires attention to prevention strategies for adverse reactions.

李曼,任金妹,谢宁. 2014~2016年我院门诊口服非甾体抗炎药的应用动态分析[J]. .

LI Man,REN Jinmei and Xie Ning. Dynamic Analysis of Oral Nonsteroid Anti-inflammatory Drugs Used in Outpatients in Our Hospital During the Year of 2014~2016[J]. .

参考文献

[1]Singh G,Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications[J]. J Rheumatol, 1999, 56(Suppl): S18-24.
[2]姚中强, 于孟学, 韩淑玲. 非甾体抗炎药[J]. 北京医学, 2005, 27(5): 295-300.
[3]左橙子, 彭文兴. 非甾体抗炎药的安全用药与合理选择[J]. 中南药学, 2017(5): 639-642.
[4]Masso Gonzalez EL, Patrignani P, Tacconelli S, et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding[J]. Arthritis Rheum, 2010, 62(6): 1592-1601.
[5]Johnson D A. Upper GI risks of NSAIDs and antiplatelet agents: key issues for the cardiologist[J]. Rev Cardiovasc Med, 2005, 6 Suppl(4): S15-22.
[6]陈新谦, 金有豫, 汤光. 新编药物学[M]. 第17 版. 北京: 人民卫生出版社, 2011: 186-203.
[7]李蕊, 王月, 谢清, 等. 2010～2012年航天中心医院住院患者抗菌药物应用分析[J].中国医院用药评价与分析, 2013, 13(10), 880.
[8]Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial(TARGET), reduction in ulcer complications: randomised controlled trial [J]. Lancet, 2004, 364(9435): 665-674.
[9]Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group[J]. N Engl J Med, 2000, 343(21): 1520-1528.
[10]Lipsky PE, Abramson SB, Crofford LJ, et al. The classification of eyelooxgenaseinhibitors[J]. The Journal of rheumatology, 1998, 25(12): 2298-2303.
[11]傅得兴, 黄公怡. 非甾体抗炎药的不良反应及改进抗炎药物治疗的新发展[J]. 中国新药杂志, 2000, 9(9): 604-608.
[12]杨宝峰, 苏定冯, 周宏灏, 等. 药理学[M]. 第7版. 北京: 人民卫生出版社, 2008: 19-190.
[13]Satoh H, Takeuchi K. Management of NSAID/aspirin-induced small intestinal damage by GI-sparing NSAIDs, anti-ulcer drugs and food constituents[J]. Curr Med Chem, 2012, 19(1) : 82-89.
[14]Garcia Rodriguez LA,Tacconelli S,Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population [J]. J Am Coll Cardiol, 2008, 52(20): 1628-1636.
[15]Pirlamarla P, Bond RM. FDA labeling of NSAIDs: Review of nonsteroidal anti-inflammatory drugs in cardiovascular disease [J]. Trends Cardiovasc Med, 2016, 26(8): 675-680.
[16]Patrignani P, Tacconelli S, Bruno A, et al. Managing the adverse effects of nonsteroidal anti-inflammatory drugs [J]. Expert Rev Clin Pharmacol, 2011, 4(5): 605-621.
[17]Bhatt D L, Scheiman J, Abraham N S, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents[J]. J Am Coll Cardiol, 2008, 52(18): 1502-1517.
[18]Lanas A, Benito P, Alonso J, et al. Safe prescription recommendations for non steroidal anti-inflammatory drugs: consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG)[J]. Reumatol Clin, 2014, 10(2): 68-84.
[19]Lanza F L, Chan F K, Quigley E M, et al. Guidelines for prevention of NSAID-related ulcer complications[J]. Am J Gastroenterol, 2009, 104(3): 728-738.
[20]苏甦, 李晓玲. 长期口服非甾体抗炎药患者的胃肠道和心血管不良反应防治策略[J]. 临床药物治疗杂志, 2017, 15(2):7-11.

快速检索引用检索图表检索高级检索